Clinical trial
Early Mineralocorticoid Receptor Antagonist Therapy for Low-Renin Essential Hypertension: A Randomized Controlled Study
NCT07932145 is registered in ClinicalTrials.gov with China National Center for Cardiovascular Diseases as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Early Mineralocorticoid Receptor Antagonist Therapy for Low-Renin Essential Hypertension: A Randomized Controlled Study
- Lead sponsor
- China National Center for Cardiovascular Diseases
- Phase
- Phase 4
- Overall status
- Not yet recruiting
- Start date
- December 1, 2026
- Completion date
- April 30, 2028
- Enrollment
- 128 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hypertension (htn), low-renin essential hypertension
Arms
As registered; 2 arms.
-
Early Eplerenone-Based Treatment
Participants will receive stepped antihypertensive treatment starting with eplerenone 50 mg orally once daily. Treatment will be intensified as needed by sequentially adding amlodipine 5 mg once daily, increasing eplerenone to 50 mg twice daily, increasing amlodipine to 5 mg twice daily, adding hydrochlorothiazide 12.5 mg once daily, adding doxazosin 4 mg once daily, and increasing hydrochlorothiazide to 25 mg once daily. Participants taking two antihypertensive drugs before washout will generally start with eplerenone plus amlodipine. Treatment adjustments will depend on blood pressure, tolerability, and safety assessments, with a target seated office blood pressure below 140/90 mmHg. Treatment will continue for 24 weeks.
-
Standard Treatment
Participants will receive stepped antihypertensive treatment starting with telmisartan 40 mg orally once daily. Treatment will be intensified as needed by sequentially adding amlodipine 5 mg once daily, increasing telmisartan to 80 mg once daily, increasing amlodipine to 5 mg twice daily, adding hydrochlorothiazide 12.5 mg once daily, adding doxazosin 4 mg once daily, and increasing hydrochlorothiazide to 25 mg once daily. Participants taking two antihypertensive drugs before washout will generally start with telmisartan plus amlodipine. Treatment adjustments will depend on blood pressure, tolerability, and safety assessments, with a target seated office blood pressure below 140/90 mmHg. Treatment will continue for 24 weeks.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Change From Baseline in Mean Daytime Ambulatory Systolic Blood Pressure at Week 12
Change in mean daytime systolic blood pressure, measured in mmHg by 24-hour ambulatory blood pressure monitoring, from baseline to Week 12. Mean daytime systolic blood pressure is the average of all valid daytime systolic readings. A valid recording requires at least 70% of scheduled readings, including at least 20 daytime readings and 7 nighttime readings. Change is calculated as the Week 12 value minus the baseline value; a negative value indicates a reduction in blood pressure.
Lead sponsor's other trials
China National Center for Cardiovascular Diseases, most recent start first.
+264 more trials See the organization page
Similar trials
Same condition (Hypertension) and phase, most recent start first.
+697 more trials See the condition page